Literature DB >> 6987861

Direct tissue visualization of normal cross-reacting antigen in neoplastic granulocytes.

P K Pattengale, C R Taylor, E Engvall, E Ruoslahti.   

Abstract

Normal cross-reacting antigen, a glycoprotein that shares some antigenic determinants with carcinoembryonic antigen, was consistently demonstrated by tissue immunoperoxidase staining in the cytoplasm of both non-neoplastic and neoplastic neutrophilic granulocytes. It was absent in lymphoid cells, but occasional cells of the macrophage/histiocyte series showed variable staining. Malignant cells from patients who had non-Hodgkin or Hodgkin lymphomas were negative for normal cross-reacting antigen. These findings were in contrast to the findings of specific normal cross-reacting antigen positivity in neoplastic granulocytes from three patients who had acute granulocytic leukemia, three who had chronic granulocytic leukemia, and one who had a granulocytic sarcoma. Similar normal cross-reacting antigen positivity was also seen in granulocytes from two patients who had granulocyte dysplasia. It is suggested that direct tissue visualization of normal cross-reacting antigen using immunoperoxidase technics may be of value in the classification and diagnosis of hematologic malignancies, and may provide an additional marker for cells of the granulocytic series.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6987861     DOI: 10.1093/ajcp/73.3.351

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Comparative evaluation of immunhistochemistry and enzyme histochemistry for granulocyte visualization in formalin-fixed and paraffin-embedded liver and lung biopsies.

Authors:  H P Dinges; H Redl
Journal:  Histochemistry       Date:  1983

2.  Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series.

Authors:  A Noworolska; A Harłozińska; R Richter; W Brodzka
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.